What happens @ PathCare?
Have a look behind the scenes to see how patient specimen
flow is regulated in our laboratory system.
- Allergy 
- Antimicrobials & infection 
- Autoimmune 
- Chemical Pathology 
- Endocrinology 
- Epidemiology 
- Gastrointestinal 
- Genetic Analysis 
- Genitourinary 
- Haematology 
- HIV/TB 
- Infectious Diseases 
- Neurology 
- Obstetric and Neonatal care 
- Oncology 
- Ophthalmology 
- Respiratory 
- Serology 
- Virology 
PathCare has introduced an antibody test that is capable of detecting antibodies directed against the SARS-CoV-2 spike (“S”) protein, induced by SARS-CoV-2 vaccines or by natural infection
Testing for respiratory pathogens using comprehensive multiplex molecular panels have become a valuable diagnostic tool to assist in early identification of causative organisms. Appropriate use supports timely and directed antimicrobial therapy, especially for organisms that cannot be routinely cultured (e.g Mycoplasma, Legionella, Chlamydophila, Bordetella, and viruses); decreases in-hospital admission rate, length of hospital stay, and also assists in antimicrobial stewardship by avoiding the use of empiric antimicrobial agents
Immune-mediated diabetes is characterized by the presence of circulating specific antibodies against the pancreatic islets such as glutamic acid decarboxylase autoantibodies (GADA), islet antigen-2 autoantibodies (IA-2A), or zinc transporter-8 autoantibodies (ZnT8A).
The presence of viral RNA in respiratory samples is critical information in the diagnosis of an acute SARS-COV-2 infection. The real-time reverse transcription-polymerase chain reaction (RT-PCR) detects these pieces of RNA. But RT-PCR is a poor test of cure. The presence of RNA does not imply the presence of infectious or replication-competent virus.
COVID-19 Antibody testing available at PathCare
Cytogenomics is used as a general term that encompasses conventional karyotyping, as well as molecular cytogenetics (fluorescence in situ hybridization-FISH), microarrays and molecular-based techniques
We have updated the PathCare susceptibility data for common community-acquired organisms isolated from patients in the Western Cape Province from the first of March 2019 until the end of February 2020
In response to the many questions being asked of us as to when we would be able to offer antibody testing; this is a brief note of explanation as to the processes we have to follow before we may offer the tests.
PathCare now offers SARS-CoV-2 / COVID-19 testing
On 31 December 2019, the World Health Organization (WHO) China country office reported a cluster of pneumonia cases in Wuhan City, Hubei Province of China. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been confirmed as the causative virus of Coronavirus disease 2019 (COVID-19). This virus has since spread to all continents and South Africa’s first case was identified on 5 March 2020.